Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.66 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841413 | 0.88 | PARP1 (0.51) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL6589989 | 0.88 | CYP11B1 (0.53) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL4837264 | 0.86 | PARP1 (0.52) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL25548688 | 0.85 | CYP2C9 (0.70) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL581787 | 0.85 | AR (0.70) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL6587665 | 0.84 | PARP1 (0.50) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL4840388 | 0.83 | GAA (0.51) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL6590866 | 0.83 | TSHR (0.48) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL4702788 | 0.82 | CYP3A4 (0.53) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL4117496 | 0.82 | GAA (0.51) | ARCYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| EP-1737840-B1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-03 | — | — | US | disclosed |
| EP-1737840-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005103033-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, GOT2 | PARP1 1732/4885AR 2300/4885CYP3A4 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.